Visionary portfolio company, Aurion Biotech, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has won the prestigious Prix Galien Award for Best Startup in Biotech / Pharma. The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, fosters, recognizes, and rewards excellence in scientific innovation to improve the state of human health. Aurion Biotech received the Best Start-up in Biotech / Pharma award, one of six different award categories, and was chosen from more than 146 products from 129 nominee companies, spanning 14 therapeutic areas. According to the Galien Foundation, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.
Aurion Biotech Raises $120 Million from Deerfield Management, Petrichor, Flying L Partners, Falcon Vision/KKR, and Visionary Ventures
Aurion Biotech, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has secured a $120 million financing with top-tier biotech and ophthalmology investors. The financing was led by Deerfield Management, and included existing investors Petrichor Healthcare Capital Management, Flying L Partners, Falcon Vision, an ophthalmology-focused investment platform supported by KKR, and Visionary Ventures, a leading ophthalmology-focused venture fund creating value with better insight. Alcon also participated in the financing. Funds will be disbursed to the Company based on the achievement of key clinical and operational milestones.